Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Shiver your way to better blood sugar? new study tests cold therapy for diabetes

NCT ID NCT05576025

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether shivering from cold exposure can improve 24-hour blood sugar levels in people with prediabetes or type 2 diabetes. Twenty-four participants underwent two cold sessions at different shivering intensities. The goal was to see if muscle activation from shivering helps the body use glucose better. It is a small, early-stage study, so results are not yet conclusive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cold exposure (shivering at different intensities)
What this could lead to
If it works, this could point toward a simple, drug-free way to help manage blood sugar in type 2 diabetes or prediabetes.
What could go wrong
This is a very small, early study (24 people) looking at short-term effects only. The results may not lead to a practical treatment, and cold exposure may be uncomfortable or risky for some.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Nov 2022

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion criteria for all subjects: * to be able to provide signed and dated written informed consent prior to any study specific procedures * have suitable veins for cannulation or repeated venepuncture * male, or postmenopausal (at least 1 year post cessation of menses) female * aged 40 - 75 years * have stable dietary habits (no weight loss or gain \>5 kg within the past 3 months) * have no signs of active cardiovascular disease or liver malfunction * have body mass index (BMI) \>= 27 and \<= 38 kg/m2 Additional inclusion criteria for pre-diabetic subjects: Pre-diabetes based on one or a combination of the following criteria: * Impaired Glucose Tolerance (IGT): plasma glucose values ≥ 7.8 mmol/l and ≤ 11.1 mmol/l 120 minutes after glucose drink consumption during OGTT in screening * ImpairedFastingGlucose(IFG):Fastingplasmaglucose≥6.1mmol/land≤6.9 mmol/l * Insulin Resistance: glucose clearance rate ≤ 360 mL/kg/min, as determined using OGIS120 * HbA1c of 5.7-6.4% Additional inclusion criteria for type 2 Diabetes Mellitus patients: * being diagnosed with T2DM at least 1.5 years before the start of the study * have well-controlled diabetes, i.e. HbA1c levels \< 8.5% * have no signs of active diabetes-related co-morbidities, including active cardiovascular diseases, diabetic foot, polyneuropathy or retinopathy * diet treatment OR on an oral glucose lowering medication: metformin only or in combination with sulfonylurea agents and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months Exclusion Criteria: * not meeting the respective inclusion criteria * participation in a clinical study with an investigational product during the last 3 months or as judged by the investigator * uncontrolled hypertension * having Hb \<8 mmol/L (men), Hb \<7 mmol/l (women) * consuming alcohol \>2 servings per day (man) or \>1 servings per day (women) * not wanting to be informed about unexpected medical findings during the screening * being engaged in structured exercise \> 2h per week * smoking * being cold-acclimated, e.g. having taken daily extended cold baths, working in a refrigerated environment, or practicing regular cold-water swimming/showering within 1 month of starting the study Exclusion criteria specific for pre-diabetic subjects: \- Type 2 Diabetes Mellitus Exclusion criteria specific for type 2 Diabetes Mellitus patients: \- being insulin-dependent and/or using SGLT2 inhibitor medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Maastricht University, Department of Nutrition and Movement Sciences

    Maastricht, Limburg, 6200MD, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.